Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model

Neoplasia

Volumn 12, Issue 5, 2010, Pages 397-404

  Tsunoda, Toshiyuki ^a   Takashima, Yasuo ^a   Fujimoto, Takahiro ^a   Koyanagi, Midori ^a   Yoshida, Yasuhiro ^a   Doi, Keiko ^a   Tanaka, Yoko ^a   Kuroki, Masahide ^a   Sasazuki, Takehiko ^b   Shirasawa, Senji ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EXO 1 PROTEIN; K RAS PROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL POLARITY; CELL STRAIN HCT116; COLORECTAL CANCER; CONTROLLED STUDY; CULTURE TECHNIQUE; DNA METABOLISM; DNA REPAIR; HUMAN; HUMAN CELL; INTESTINE CRYPT; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 77951682920     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10170     Document Type: Article

References (46)

1. O'Brien LE, Zegers MM, and Mostov KE (2002). Opinion: Building epithelial architecture: insights from three-dimensional culture models. Nat Rev Mol Cell Biol 3, 531-537.
2. Griffith LG and Swartz MA (2006). Capturingcomplex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 7, 211-224.
3. Birgersdotter A, Sandberg R, and Ernberg I (2005). Gene expression perturbation in vitro-a growing case for three-dimensional (3D) culture systems. Semin Cancer Biol 15, 405-412.
4. Bissell MJ and Labarge MA (2005). Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7, 17-23.
5. Yamada KM and Cukierman E (2007). Modeling tissue morphogenesis and cancer in 3D. Cell 130, 601-610.
6. Huber MA, Kraut N, and Beug H (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17, 548-558.
7. Thiery JP and Sleeman JP (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7, 131-142.
8. Wodarz A and Nathke I (2007). Cell polarity in development and cancer. Nat Cell Biol 9, 1016-1024.
9. McDonald SA, Preston SL, Lovell MJ, Wright NA, and Jankowski JA (2006). Mechanisms of disease: from stem cells to colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 3, 267-274.
10. Cho KK and Vogelstein B (1992). Genetic alterations in the adenoma-carcinoma sequence. Cancer 70, 1727-1731.
11. Hanahan D and Weinberg RA (2004). The hallmarks of cancer. Cell 100, 57-70.
12. Vogelstein B and Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med 10, 789-799.
13. Kinzler KW and Vogelstein B (1998). Colorectal tumors. In The Genetic Basis of Human Cancer. B Vogelstein and KW Kinzler (Eds). McGraw-Hill, New York, NY. pp. 565-587.
14. Rosin-Arbesfeld R, Ihrke G, and Bienz M (2001). Actin-dependent membrane association of the APC tumour suppressor in polarized mammalian epithelial cells. EMBO J 20, 5929-5939.
15. Maire G, Yoshimoto M, Chilton-MacNeill S, Thorner PS, Zielenska M, and Squire JA (2009). Recurrent RECQL4 imbalance and increased gene expression levels are associated with structural chromosomal instability (S-CIN) in sporadic osteosarcoma. Neoplasia 11, 260-268.
16. Cho JY, Kim JH, Lee YH, Chung KY, Kim SK, Gong SJ, You NC, Chung HC, Roh JK, and Kim BS (1997). Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer 79, 462-467.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359,1757-1765.
18. Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, et al. (2009). Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 11,1084-1092.
19. Shirasawa S, Furuse M, Yokoyama N, and Sasazuki T (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260, 85-88.
20. Shirasawa S and Sasazuki T (2003). The impact of oncogenes on tumor maintenance. In Oncogene-Directed Therapies. JW Rak (Ed). Human Press, Inc, Totowa, NJ. pp. 229-243.
21. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, and Rak JW (2005). Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105, 1734-1741.
22. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, Rojas A, Song X, Ulrich CM, Sasazuki T, Shirasawa S, et al. (2009). TGF-β receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a β-catenin-independent pathway. Gastroenterology 136, 1680-1688.
23. Baba I, Shirasawa S, Iwamoto R, Okumura K, Tsunoda T, Nishioka M, Fukuyama K, Yamamoto K, Mekada E, and Sasazuki T (2000). Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-ras signaling pathway in human colon cancer cells. Cancer Res 60, 6886-6889.
24. Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK, and Shirasawa S (2009). The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate 69, 1398-1403.
25. Debnath J, Muthuswamy SK, and Brugge JS (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268.
26. Koyanagi M, Nakabayashi K, Fujimoto T, Gu N, Baba I, Takashima Y, Doi K, Harada H, Kato N, Sasazuki T, et al. (2008). ZFAT expression in B and T lymphocytes and identification of ZFAT-regulated genes. Genomics 91, 451-457.
27. Bubner B, Gase K, and Baldwin IT (2004). Two-fold differences are the detection limit for determining transgene copy numbers in plants by real-time PCR. BMC Biotechnol 4, 14.
28. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25,402-408.
29. Fujimoto T, Miyasaka K, Koyanagi M, Tsunoda T, Baba I, Doi K, Ohta M, Kato N, Sasazuki T, and Shirasawa S (2009). Altered energy homeostasis and resistance to diet-induced obesity in KRAP-deficient mice. PLoS One 4, e4240.
30. Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, Lightcap ES, Veiby OP, and Brugge JS (2007). Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci USA 104, 3787-3792.
31. Mao Z, Jiang Y, Liu X, Seluanov A, and Gorbunova V (2009). DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia 11, 683-691.
32. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71.
33. Zheng L, Li S, Boyer TG, and Lee WH (2000). Lessons learned from BRCA1 and BRCA2. Oncogene 19, 6159-6175.
34. Kastan MB and Bartek J (2004). Cell-cycle checkpoints and cancer. Nature 432, 316-323.
35. Naseem R and Webb M (2008). Analysis of the DNA binding activity of BRCA1 and its modulation by the tumour suppressor p53. PLoS One 3, e2336.
36. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, and Micklem G (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792.
37. Bolderson E, Richard DJ, Zhou BB, and Khanna KK (2009). Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 15, 6314-6320.
38. Schmutte C, Marinescu RC, Sadoff MM, Guerrette S, Overhauser J, and Fishel R (1998). Human exonuclease I interacts with the mismatch repair protein hMSH2. Cancer Res 58, 4537-4542.
39. Kucherlapati M, Nguyen A, Kuraguchi M, Yang K, Fan K, Bronson R, Wei K, Lipkin M, Edelmann W, and Kucherlapati R (2007). Tumor progression in Apc(1638N) mice with Exo1 and Fen1 deficiencies. Oncogene 26, 6297-6306.
40. Mimitou EP and Symington LS (2008). Sae2, Exo1 and Sgs1 collaborate in DNA double-strand break processing. Nature 455, 770-774.
41. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217-221.
42. Vogelstein B and Kinzler KW (1992). p53 function and dysfunction. Cell 70, 523-526.
43. Halazonetis TD, Gorgoulis VG, and Bartek J (2008). An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355.
44. Oberreuther-Moschner DL, Rechkemmer G, and Pool-Zobel BL (2005). Basal colon crypt cells are more sensitive than surface cells toward hydrogen peroxide, a factor of oxidative stress. Toxicol Lett 159, 212-218.
45. Hong MY, Turner ND, Carroll RJ, Chapkin RS, and Lupton JR (2005). Differential response to DNA damage may explain different cancer susceptibility between small and large intestine. Exp Biol Med 230, 464-471.
46. Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, and Gilks CB (2009). MicroRNA profiling of BRCA1/2 mutationcarrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 4, e7314.